Lymphoblastic Lymphoma In Adults
Lymphoblastic lymphoma (LBL) accounts for approximately 4% of all adult patients with non-Hodgkin’s lymphoma (NHL). It is recognised as a distinct clinopathological entity in all of the recently described classifications for NHL, including the Revised European-AmeriPcan Lymphoma (REAL) classification. It is a neoplasm of precursor T or B lymphocytes, which is very similar to acute lymphoblastic leukaemia on the basis of morphology and phenotype. The distinction between ALL and LBL is variable between different treatment centres, and usually based on arbitrary clinical grounds, particularly the degree of bone marrow infiltration or leukaemic overspill. Because of its rarity, it has been the subject of relatively few series in the published literature, and several aspects of its management remain unclear. The results of treatment have improved in recent years, particularly with the use of intensive remission induction therapy similar to that used in acute lymphoblastic leukaemia (ALL). With intensive chemoradiotherapy, most recent series have reported remission rates of 60% to 80%, with long term disease free survival reported in 40% to 60% of patients. Therefore, although high remission rates can be achieved with conventional dose combination chemotherapy, the relapse and progression rate is high. The use of dose intensive therapy in first remission, particularly high dose therapy with stem cell transplantation, has been reported in several series, although its role remains unclear. Similarly, the selection of patients who are at high risk of relapse or progression with conventional therapy has not been reported consistently. The optimal management of patients who fail first line therapy also remains a difficult clinical problem.
KeywordsOverall Survival Clin Oncol Autologous Stem Cell Transplanatation Acute Lymphoblastic Leukaemia Autologous Bone Marrow
Unable to display preview. Download preview PDF.
- 7.. Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1626– 1637Google Scholar
- 8.. Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: A report on 80 patients. J Clin Oncol 1992; 10: 1078 – 1085Google Scholar
- Bernasconi C, Brusamolino E, Lazzarino M, et al. Lymphoblastic lymphoma in adult patients; Clinico-pathological features and response to intensive multi agent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1990; 1: 141 – 146Google Scholar
- Sweetenham JW, Mead GM, Whitehouse JMA. Adult lymphoblastic lymphoma: High incidence of central nervous system relapse in patients treated with the Stanford University protocol. Ann Oncol 1992; 3: 839 –841Google Scholar
- 12.. Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin’s lymphoma in children. A progress report on the original patients treated with the LSA2L2 protocol. Cancer 1979; 44: 1990 – 1999Google Scholar
- The International Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987 – 994Google Scholar
- Jackson GH, Lennard AL, Taylor PRA, et al. Autologous bone marrow transplantation in poor risk high grade non-Hodgkin’s lymphoma in first complete remission. Br J Cancer 1994; 70: 501 – 505Google Scholar
- 18.. Sweetenham JW, Liberti G, Pearce R, et al. High dose therapy and autologous bone marrow transplanta¬tion for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358 – 1365Google Scholar
- 20.. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992; 11: 1690 – 1695Google Scholar
- 21.Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous bone marrow into breast cancer patients following high dose chemotherapy: influence of CD34-positive pripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28 – 31PubMedGoogle Scholar
- 22.Haas R, Witt B, Goldschmidt H, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754 – 3761Google Scholar